Physician profile
William A Martinez
NPI 1144212382
$4,938.21
in general payments reported to CMS, 2019-2025
24 companies · $1,274 in 2025
The $1,274 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $734 · 2020: $408 · 2021: $472 · 2022: $418 · 2023: $350 · 2024: $1,283 · 2025: $1,274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,861 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,861.45 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,151.66 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $837.52 | 2019-2025 | Jardiance, Trijardy Xr |
| Lilly USA, LLC | $745.98 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $644.76 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Sanofi-Aventis U.S. LLC | $345.88 | 2019-2022 | |
| Abbott Laboratories | $306.99 | 2024-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $279.72 | 2019-2022 | |
| Pfizer INC. | $162.03 | 2023-2025 | |
| Glaxosmithkline, LLC. | $68.47 | 2020-2023 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $59.17 | 2019-2021 | |
| Amgen INC. | $41.67 | 2019 | |
| Abbvie INC. | $33.95 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $33.83 | 2024-2025 | Zoryve |
| Harmony Biosciences LLC | $31.85 | 2023 | Wakix |
| Melinta Therapeutics, LLC | $29.60 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $29.02 | 2025 | |
| Hologic Sales and Service, LLC | $21.72 | 2022 | |
| Mannkind Corporation | $21.02 | 2019 | |
| Allergan, INC. | $20.69 | 2019 | |
| Ardelyx, INC. | $17.67 | 2024 | Ibsrela |
| Dermira, INC. | $17.02 | 2020 | |
| Xeris Pharmaceuticals, INC. | $14.25 | 2022 | |
| Horizon Therapeutics Plc | $11.99 | 2021 | |
| Philips North America LLC | $11.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.